Background-We recently demonstrated that the sarcolemmal ATP-sensitive potassium (sarcK ATP ) channel plays a key role in cardioprotection against ischemia/reperfusion injuries in Kir6.2-knockout (KO) mice. In the present study, we evaluated the effects of diazoxide, a mitochondrial ATP-sensitive potassium (mitoK ATP ) channel opener, on ischemiainduced myocardial stunning in sarcK ATP channel-deficient mice. 
A TP-sensitive potassium (K ATP ) channels play an important role in cardiovascular system. Our recent study using Kir6.2-deficient (KO) mice revealed that Kir6.2 forms the pore region of the cardiac sarcolemmal K ATP (sarcK ATP ) channel but not that of the vascular sarcK ATP channel. 1, 2 In addition, neither Kir6.2 nor Kir6.1 seems to be a constituent of the mitochondrial K ATP (mitoK ATP ) channel in cardiomyocytes, 2, 3 as assessed by flavoprotein oxidation assay. Recently, it was postulated that activation of mitoK ATP channels rather than sarcK ATP channels is important in cardioprotection against ischemia/reperfusion injuries, and that diazoxide and 5-hydroxydecanoate (5-HD) are a mitoK ATP -specific opener and blocker, respectively. 4 -9 This conclusion was based on pharmacological data, however, and the molecular identity of the mitoK ATP channel has not been established.
We recently found that ischemic preconditioning is abolished in sarcK ATP channel-deficient mice despite intact mitoK ATP channel function. 3 It is unclear whether diazoxide can exert cardioprotective effect, however, even if the sarcK ATP channel is negated. In the present study, we performed functional analysis of wild-type (WT) and knockout (KO) mouse hearts subjected to ischemia/reperfusion, and we show that the activity of the sarcK ATP channel is essential for diazoxide-induced anti-stunning effect, possibly caused by the reduced cardiac excitability when they are open.
Methods

Kir6.2 -/-Mice
All procedures complied with National Institutes of Health standards for the care and use of animal subjects. A mouse line deficient in K ATP channels was generated by targeted disruption of the gene coding for Kir6.2, as described previously. 10 C57BL/6 mice from our laboratory were used as controls because the knockout animals had been backcrossed to a C57BL/6 strain for 5 generations.
In Vitro Functional Study Using Langendorff-Perfused Hearts
Functional study using isolated mouse hearts was performed as previously described. 
Action Potential Recordings in Coronary-Perfused Ventricular Preparations
The heart was isolated and perfused at a constant flow (2 mL/min) with the Tyrode solution containing (in mmol/L): NaCl 125, KCl 4, NaH 2 PO 4 1.8, MgCl 2 0.5, CaCl 2 2.7, glucose 5.5, and NaHCO 3 25, and gassed with 95% O 2 /5% CO 2 . The right and left atria, right ventricular free wall, and septum were removed. Coronary-perfused ventricular muscle preparations stimulated at 5 Hz were subjected to no-flow global ischemia. Action potentials (APs) were recorded with conventional microelectrode. Diazoxide was applied 10 minutes before the ischemic period.
Drugs
The drugs used were 5-HD, diazoxide (Sigma), and HMR1098
-methylthiourea, Aventis Pharma, Tokyo, Japan). Diazoxide was dissolved in DMSO, and the final concentration of solvent was 0.01%. HMR1098 and 5-HD were dissolved in the perfusate.
Statistics
All data are presented as meanϮSEM. Statistical analyses of the data were performed using Student's t test or ANOVA. Probability values less than 0.05 were considered significant.
Results
There were no significant differences in baseline values of heart rate, left ventricular developed pressure (LVDP), and CPP among the 6 experimental groups: control WT (WT- 3 The increase in EDP at 15 minutes of ischemia was significantly greater in KO than WT hearts (Figure 1b) . Diazoxide slightly attenuated the increase in EDP in WT (WT-DZ, not significant) but not KO hearts (KO-DZ). Coadministration of HMR1098 abolished the lessening effect of diazoxide on the increase in EDP in WT hearts (PϽ0.05), whereas addition of 5-HD to diazoxide slightly and insignificantly enhanced the increase in EDP (Figure 1b) .
After reperfusion, LV contractile function recovered gradually. Treatment with diazoxide significantly improved the recovery of LV function in WT hearts (Figure 1c) . However, diazoxide did not improve the recovery of LV function in KO hearts. In addition, the recovery of LV function in WT-DZϩHMR hearts was similar to that in both KO groups (KO-CON, KO-DZ). Coadministration of 5-HD (WT-DZϩ5HD) did not significantly affect the diazoxide-induced protective effect (Figure 1c ). These findings indicate that activation of sarcK ATP rather than mitoK ATP channels is necessary for diazoxide-induced cardioprotection.
To determine if diazoxide activates sarcK ATP channels during ischemia in WT hearts, we measured APs in coronaryperfused ventricular muscle preparations. The preischemic values of AP duration at 90% repolarization (APD 90 ) and resting membrane potential in control (untreated) WT hearts (nϭ5) and diazoxide-treated WT hearts (nϭ5) were 61.4Ϯ3.7 ms and Ϫ71.6Ϯ2.4 mV and 58.0Ϯ4.4 ms and Ϫ73.7Ϯ3.4 mV, respectively. There were no significant differences between the baseline values. After induction of global ischemia, APD gradually decreased in untreated WT hearts (Figure 2a) . Treatment with diazoxide significantly accelerated the action potential shortening during ischemia (Figure 2b) . APD 90 at 2 minutes after ischemia in untreated and diazoxide-treated WT hearts were 50.4Ϯ4.1 ms and 17.2Ϯ2.5 ms, respectively (PϽ0.05) (Figure 2c ). These findings indicate that diazoxide activates sarcK ATP channels and enhances AP shortening during ischemia.
Discussion
Diazoxide is generally thought to be a mitoK ATP channelspecific opener in cardiomyocytes. In addition, diazoxide induces no sarcolemmal K ATP currents using nystatinperforated patch-clamp techniques in isolated mouse ventricular cells (Suzuki et al, unpublished observations, 2001 ), as has been reported also in other species. 4, 8, 11 Because diazoxide produces a flavoprotein oxidation that reflects similar openings of mitoK ATP channels in ventricular cells of both WT and Kir6.2-deficient mice, 3 diazoxide should have a similar mitoK ATP channel-mediated cardioprotective effect. However, diazoxide significantly improved the recovery of left ventricular function after ischemia/reperfusion in WT but not in KO hearts in this study. These diazoxide-induced cardioprotective effects were abolished by coadministration of HMR1098 but not 5-HD, further indicating that the cardioprotective effect is mediated by sarcK ATP channels but not mitoK ATP channels. In addition, diazoxide shortened APD during myocardial ischemia in coronary-perfused ventricular muscle preparations of WT mice. These findings strongly suggest that in mice hearts, diazoxide activates sarcK ATP channels and shortens the action potential duration during ischemia, thereby blunting intracellular Ca 2ϩ overload. Recently, Matsuoka et al 12 and D'hahan et al 13 reported that diazoxide activates sarcK ATP channels during simulated ischemia or when ADP is added in reconstituted channels (Kir6.2/SUR2A) or guinea pig ventricular myocytes, in accord with our findings. During myocardial ischemia, the intracellular ADP level might increase sufficiently to allow diazoxide to activate the sarcK ATP channels. Because ischemia-induced action potential shortening occurred more rapidly in the presence of diazoxide (Figure 2 ), intracellular Ca 2ϩ overload might well be lessened and the recovery of left ventricular function after reperfusion improved.
It should be noted that in our studies contractile function but not infarct size was measured, we did not give any mitoK ATP openers other than diazoxide, and direct assessment of mitoK ATP channel activity was not performed, although our previous study showed that mitoK ATP channel activity, indirectly assessed by flavoprotein fluorescence measurement, was preserved. 3 These facts potentially limit the interpretation of our findings. In addition, role of sarcK ATP against ischemia/reperfusion injuries might be exaggerated in mouse relative to larger animals, as mouse is a species in which the physiological heart rate is approximately 10-fold higher than in humans. In this context, it is noteworthy that in rat, cardioprotective doses of diazoxide did not shorten APD during ischemia, and the cardioprotection by diazoxide was blocked by 5-HD but not by HMR1098. 4, 7 Therefore, the findings obtained from mouse hearts cannot be directly extrapolated to clinical settings.
In conclusion, diazoxide-induced protective effect on the ischemia-induced contractile dysfunction of mouse heart is mediated by accelerated activation of sarcK ATP channels during ischemia, suggesting that activation of sarcK ATP channels rather than of mitoK ATP channels is important for diazoxide-induced anti-stunning effect. 
